000			01697 a2200457 4500
005			20250517221359.0
264		0	_c20180926
008			201809s 0 0 eng d
022			_a1543-0790
040			_aNLM _beng _cNLM
100	1		_aDomchek, Susan M
245	0	0	_aThe evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. _h[electronic resource]
260			_bClinical advances in hematology & oncology : H&O _cMay 2018
300			_a330-332 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aBRCA1 Protein _xantagonists & inhibitors
650	0	4	_aBRCA2 Protein _xantagonists & inhibitors
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCapecitabine _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aFurans _xtherapeutic use
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aIndazoles _xtherapeutic use
650	0	4	_aIndoles _xtherapeutic use
650	0	4	_aKetones _xtherapeutic use
650	0	4	_aMutation
650	0	4	_aPhthalazines _xtherapeutic use
650	0	4	_aPiperazines _xtherapeutic use
650	0	4	_aPiperidines _xtherapeutic use
650	0	4	_aPoly(ADP-ribose) Polymerase Inhibitors _xtherapeutic use
650	0	4	_aPoly(ADP-ribose) Polymerases _xgenetics
650	0	4	_aPrognosis
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSurvival Analysis
650	0	4	_aVinblastine _xanalogs & derivatives
650	0	4	_aVinorelbine
773	0		_tClinical advances in hematology & oncology : H&O _gvol. 16 _gno. 5 _gp. 330-332
999			_c28480632 _d28480632